On Jan. 20, the House of Representatives passed a health care spending package. Among the proposed policies is a provision for Medicare coverage of multi-cancer early detection (MCED) tests, pending Food and Drug Administration approval.
While this may seem like a win for cancer care, oncologists and their patients should approach widespread adoption of MCED tests with caution.
Detecting cancer in its earliest stages through screening, then treating it effectively, has saved millions of lives. Over the years, newer technologies have brought innovation to early detection, sharpening screening methods and making them more accessible, the latest being an at-home testing option for cervical cancer precursors.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
